Xiamen Cardiovascular Hospital Xiamen University

What Xiamen Cardiovascular Hospital Xiamen University does

Xiamen Cardiovascular Hospital Xiamen University (XMCH), also branded as Xiamen Heart Center, is a National Tertiary Cardiovascular Hospital and the only tertiary cardiovascular specialty hospital in Fujian Province, China. It serves approximately 290,000 patients annually across 600 beds, completing 21,500 interventional and open surgeries per year. The hospital is designated as a National Regional Medical Center for Cardiovascular Disease and a sub-center of the National Clinical Research Center for Cardiovascular Disease, jointly overseen by the National Health Commission and Fujian Provincial Government, and operates under Xiamen University governance.

XMCH's clinical offering spans advanced interventional procedures including Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Edge-to-Edge Repair (TEER), K-Clip tricuspid valve annuloplasty, Intravascular Lithotripsy (IVL), and the proprietary μFR system for FFR/PCI planning. Underlying technology platforms include a domestically developed cardiac surgery robotic system with independent intellectual property rights (used for robotic-assisted mitral valve repair), a VR/5G/cloud interventional cardiology training platform co-developed with China Telecom and Abbott, an AI-enabled Remote ECG Platform, and a research-stage activatable fluorescent probe (CNP2-B) for atherosclerosis imaging.

XMCH generates revenue through standard public hospital patient service delivery in China, supplemented by emerging international medical services for Belt and Road and BRICS country patients through its newly inaugurated International Medical Center. The hospital operates the Heart Sapling Visiting Scholar Program (15-20 international trainees annually, 6-12 month tenure) and the BRICS Cardiovascular Health Innovation Center, and has established strategic partnerships with hospitals in Brazil, Indonesia, El Salvador, India, Belarus, Vietnam, Myanmar, and Canada. Phase II expansion construction commenced in 2024 with international medical services as a focal area.

Name

Xiamen Cardiovascular Hospital Xiamen University

Legal name

Xiamen Cardiovascular Hospital Xiamen University

Website

https://en.xmheart.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Xiamen Cardiovascular Hospital Xiamen University is a National Tertiary Cardiovascular Hospital in Fujian, China, serving 290,000 patients annually across 600 beds. It provides advanced interventional cardiology (TAVR, TEER, robotic-assisted surgery) and operates international training and medical tourism programs for BRICS and Belt and Road countries.

Ownership category

akta.pro rank

Headquarters

HQ city

Xiamen

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Distribution channels3 records

Marketing channels4 records

Core offering

Xiamen Cardiovascular Hospital Xiamen University is a National Tertiary Cardiovascular Hospital providing advanced cardiovascular diagnosis, interventional and surgical treatment (including TAVR, robotic-assisted TEER, K-Clip tricuspid valve annuloplasty, IVL, and μFR procedures), and emergency, outpatient, inpatient, and health management services. The hospital also delivers international physician training through the Heart Sapling Program and BRICS Cardiovascular Health Innovation Center, while co-developing robotic cardiac surgery systems with domestic medical device companies.

Product overview

Xiamen Cardiovascular Hospital Xiamen University operates as a National Tertiary Cardiovascular Hospital offering comprehensive cardiovascular care services including health management, emergency care, outpatient and inpatient services. The hospital's core medical offerings span advanced interventional procedures including Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Edge-to-Edge Repair (TEER) using robotic-assisted and manual techniques, K-Clip tricuspid valve annuloplasty, Intravascular Lithotripsy (IVL), and μFR coronary physiology analysis. Supporting these clinical services are technology platforms including the Interventional Cardiology Training Platform (VR/5G/cloud-based), the Cardiac Surgery Robotic System (domestically developed for TEER procedures), and the Remote ECG Platform with AI capabilities. The hospital also operates international programs including the BRICS Cardiovascular Health Innovation Center, the Heart Sapling Visiting Scholar Program for training young cardiovascular physicians from BRICS/Belt and Road countries, and an International Medical Center for serving foreign patients. The Cardiovascular Health Industry Technology Innovation Consortium facilitates industry-academia-research integration for medical device innovation.

Differentiator

Problem solved

Functional benefit

Brands

• BRICS Innovation Center: Platform dedicated to promoting cardiovascular health exchanges, cooperation, and innovative development among BRICS countries.
• Heart Sapling Program

Quantifiable outcome

• 290,000 patients served annually
• +3 more outcomes

Named customers5 records

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature5 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• St. Paul's Hospital Vancouver General Hospital (Canada)coreStrategic or Co-development Partner · 1 October 2024Professor Wang Yan guided Professor Anson Cheung's team in completing Canada's first K-Clip transcatheter tricuspid valve annuloplasty. This established Sino-Canadian tricuspid valve repair technology exchange partnership.
• Dr. Soetomo General Academic Hospital (Indonesia)coreStrategic or Co-development Partner · 7 August 2024XMCH signed cooperation agreement with Dr. Soetomo Hospital in Surabaya, Indonesia. Both parties signed MOU focusing on deepening cooperation in clinical diagnosis and treatment, technological innovation, and talent development. XMCH team guided first TAVR in Eastern Indonesia and first IVL procedure in Indonesia.
• Minsk Surgical, Transplantation, and Hematology Science Practice Center (Belarus)coreStrategic or Co-development Partner · 1 August 2024Professor Oleg Rummo, Academician of National Academy of Sciences of Belarus, appointed as overseas distinguished physician at XMCH. Both institutions signed memorandum of cooperation covering organ transplantation, clinical research, talent cultivation, international exchanges, and technology transfer.
• Gary Roubin (Internationally Renowned Cardiovascular Expert)coreStrategic or Co-development Partner · 14 June 2024Gary Roubin, pioneer of interventional cardiology and inventor of world's first coronary stent, visited for International Medical Center inauguration. Named catheterization laboratory after him in 2005. Provides ongoing advisory and academic exchange support.
• Hospital Nacional Rosales (El Salvador)coreStrategic or Co-development Partner · 22 April 2024XMCH signed memorandum of cooperation with Hospital Nacional Rosales of El Salvador. Witnessed by Chinese Ambassador to El Salvador and Deputy Minister of Health of El Salvador. XMCH guided local team in performing TAVR using VitaFlow Liberty and completed minimally invasive aortic valve replacement.
• Hospital de Messejana (Brazil)coreStrategic or Co-development Partner · 1 April 2024XMCH signed cooperation agreement with Hospital de Messejana in Fortaleza, Brazil, covering comprehensive collaboration in cardiovascular disease diagnosis and treatment technologies, medical management, scientific research, and talent development. Hospital de Messejana sent Dr. Antonio Simao for six-month structural heart disease training under Heart Sapling Program.
• Pernambuco Heart Institute (Brazil)coreStrategic or Co-development Partner · 19 September 2023XMCH signed a Memorandum of Understanding with the Pernambuco Heart Institute of Brazil. Both parties established a regular cooperation mechanism in areas including cardiovascular clinical diagnosis and treatment, scientific research, and technical training. The Brazilian delegation toured XMCH focusing on specialized cardiovascular development, diagnosis of complex cases, smart healthcare applications, and international exchange.
• Xiamen Cardiovascular Health Industry-Technology Innovation AlliancecoreStrategic or Co-development Partner · 8 September 2023XMCH spearheaded the alliance with 12 initial member units including Tan Kah Kee Innovation Laboratory, Xiang An Biomedicine Laboratory, MicroPort, and various biomedical companies to create cardiovascular industry ecosystem through industry-academia-research collaboration.
• Indonesian Chinese Entrepreneur AssociationminorGTM or Marketing Partner · 1 September 2023XMCH delegation visited Jakarta and met with association leadership to explore international medical cooperation, talent exchange, and medical technology industry collaboration. Both sides conducted cardiovascular health lecture and cardiac emergency training.
• Apollo Hospitals Group (India)coreStrategic or Co-development Partner · 30 September 2022At the inauguration of BRICS Cardiovascular Health Innovation Center, XMCH signed letter of intent with Apollo Hospitals Group to carry out in-depth cooperation in medical technology, clinical research, talent training, academic exchange, and smart hospital development.

Scale indicators8 records

Recent moves9 records

Expansion highlights6 records

Regional players

• Medanta – The Medicity (Heart Institute): India-based multi-specialty quaternary hospital with a dedicated heart institute performing TAVR, robotic cardiac surgery, and complex interventions. Comparable as a regional tertiary cardiac center with international training and patient ambitions similar to XMCH.
• Mount Elizabeth Hospital (Singapore): Singapore private tertiary hospital with a renowned cardiology and cardiac surgery program. Comparable as a regional specialty cardiac destination for Southeast Asian patients, competing with XMCH for international referrals.
• Asian Heart Institute: Mumbai-based specialty cardiac hospital. Comparable as a tertiary cardiovascular hospital focused on complex interventional and surgical care in South Asia, overlapping with XMCH in international medical tourism and Heart Sapling-style training cohorts.
• Bumrungrad International Hospital: Thailand-based leading international medical tourism hospital with a strong cardiac program. Comparable as a regional player in inbound international cardiac care across Southeast Asia, overlapping with XMCH's Belt-and-Road patient ambitions.

Direct peers

• Fuwai Hospital, National Center for Cardiovascular Diseases: China's flagship cardiovascular specialty hospital, jointly run by the National Health Commission and Chinese Academy of Medical Sciences. Directly comparable as a tertiary cardiac hospital with national-center status, large procedural volume, and a domestic Chinese device adoption role.
• Guangdong Provincial People's Hospital (Guangdong Cardiovascular Institute): One of China's leading cardiac specialty centers with high-volume interventional and surgical programs. Comparable as a tertiary cardiovascular hospital performing TAVR, TEER, and structural heart work, competing for the same national/international patient pools.

Broad incumbents

• West China Hospital of Sichuan University: A top-tier Chinese academic medical center with a major cardiovascular center. Comparable as a tertiary academic hospital performing advanced interventional cardiology; broader than XMCH's specialty focus but competing for complex cases and Belt-and-Road referrals.
• Apollo Hospitals (Cardiac Sciences): India's largest hospital chain with a high-volume cardiac program and an existing LOI partnership with XMCH. Comparable as a multi-hospital specialty cardiac provider and a natural counterparty for BRICS training and patient referrals.
• Cleveland Clinic Heart, Vascular & Thoracic Institute: U.S.-based global leader in cardiovascular care and training. Comparable as a reference center for complex interventional cardiology and structural heart programs and a benchmark for training ecosystem design.
• Cedars-Sinai Smidt Heart Institute: U.S.-based tertiary cardiovascular center with a major structural heart and robotic cardiac surgery program. Comparable as a high-volume specialty heart institute focused on complex interventions and physician training.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xiamen Cardiovascular Hospital Xiamen University